StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Biologics Facility Huningue, France (m²) by Year

Novartis Biologics Facility Huningue, France (m²): 41,000 in FY2025, unchanged from a year earlier.

Latest, FY2025
41,000
Period ended Dec 31, 2025
Change on a year earlier
0.0%
41,000 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Huningue, France | 41 000 | Production of drug substances for clinical and commercial supply”

Source: Novartis Form 20-F (0001114448-26-000004) ↗

Reported in Form 20-F Item 4.D.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBiologics Facility Huningue, France (m²)Year on yearSource
FY2025Dec 31, 202541,0000.0%Novartis Form 20-F (0001114448-26-000004) ↗
FY2024Dec 31, 202441,000+17.1%Novartis Form 20-F (0001370368-25-000004) ↗
FY2023Dec 31, 202335,000–Novartis Form 20-F (0001370368-24-000004) ↗

Cite this data

StockData. (2026). Novartis Biologics Facility Huningue, France (m²), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/fac-huningue-m2

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.